Hematology Times
|
LymphomasMacrophages provide new approach for cancer vaccines
Macrophage in a mouse
Source: Flickr Researchers say they’ve discovered another viable approach for cancer vaccines: using the macrophage pathway to program killer T cells against cancers. The team had previously shown that nearly all cancer cells use the molecule CD47 to escape from being eliminated by macrophages. The group also found that anti-CD47 antibodies, which can block CD47’s signal and enable macrophages to engulf cancer cells, inhibited the growth of various hematologic cancers and solid tumors. [Read Article] Risk of hematologic, other cancers after CT scans
Patient undergoing a CT scan
Credit: Angela Mary Butler A large, population-based study has provided additional insight into the risk of hematologic and solid tumor malignancies associated with CT scans. Previous research has suggested CT scans pose cancer risks, particularly following exposures in childhood. However, most studies have estimated risks indirectly, and some radiation experts have questioned the validity of these estimates. To provide more definitive data, John D. Mathews, MD, PhD, of the University of Melbourne in Australia . . . [Read Article] Improving QoL for survivors of lymphoma, other cancers
Doctor consults with cancer
patient and her father Credit: Rhoda Baer A newly published review suggests survivors of lymphomas and other cancers often have significant physical and psychological impairments resulting from treatments. And these impairments often go undetected and untreated, which can lead to disabilities. However, addressing the impairments—with preventative measures prior to cancer treatment and through rehabilitation after treatment—can significantly improve survivors’ quality of life (QoL), according . . . [Read Article] Depression linked to early death in cancer survivors
Sad woman
Credit: Jiri Hodan In a large study, depressed cancer survivors were twice as likely to die prematurely as those who did not suffer from depression. The study covered a number of malignancies, including lymphoma and multiple myeloma, but the risk of death proved to be independent of cancer type. Floortje Mols, PhD, of Tilburg University in The Netherlands, and her colleagues conducted this research and described the results in Journal of Cancer Survivorship. [Read Article] Combo can override resistance in CLL
Alan Eastman, PhD
Credit: Jon Gilbert Fox A BH3 mimetic and a BCL2 inhibitor, when administered in combination, can induce apoptosis in resistant chronic lymphocytic leukemia (CLL) cells, a preclinical study suggests. Though BCL2 inhibitors have demonstrated efficacy against CLL, leukemia cells residing in lymph nodes and the bone marrow have proved resistant to these drugs. But now, researchers have found that by introducing the BH3 mimetic gossypol, they can sensitize CLL cells to the BCL2 inhibitor ABT-737. [Read Article] |
|